Prognostic role of neutrophil to lymphocyte ratio in advanced melanoma treated with anti-programmed death-1 therapy

J Dermatol. 2018 Sep;45(9):e250-e251. doi: 10.1111/1346-8138.14297. Epub 2018 Mar 23.

Authors

Tomoyuki Minowa¹, Junji Kato¹, Tokimasa Hida¹, Kohei Horimoto¹, Sayuri Sato¹, Masahide Sawada¹, Hisashi Uhara¹

Affiliation

¹ Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.

PMID: 29572922
DOI: 10.1111/1346-8138.14297

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological / therapeutic use*
Feasibility Studies
Female
Humans
Lymphocyte Count
Lymphocytes*
Male
Melanoma / blood
Melanoma / drug therapy*
Melanoma / mortality
Middle Aged
Neutrophils*
Predictive Value of Tests
Prognosis
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Skin Neoplasms / blood
Skin Neoplasms / drug therapy*
Skin Neoplasms / mortality
Survival Analysis
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
PDCD1 protein, human
Programmed Cell Death 1 Receptor